Antonella Abi Sleimen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Antonella Abi Sleimen has a total of 31 co-authors. Here are the top co-authors by number of shared publications:
- Alex Hlavaty
University Grenoble Alpes, Pharmacovigilance Unit and Clinical Pharmacology Department (CIC-1406), Grenoble Alpes University Hospital, Grenoble, France (C.K., A.H.).
1 shared publication Alice Bourgeois
CRIUCPQ, Quebec, Canada
1 shared publication- Charles Antoine Guay
Centre de Recherche de l’Institut Universitaire de Cardiologie et de Pneumologie de Québec, Québec, QC, Canada (V.T., M.M., C.A.G., R.E.K., C. Bilodeau, Y.G., S.M., S.B.-B., A.A.-S., O.B., S.P., S.B., F.P.).
1 shared publication - Charles Khouri
Université Grenoble Alpes, INSERM U1300, HP2, and INSERM CIC1406, Grenoble, France (C.J.-B., C.K.).
1 shared publication Charlotte Romanet
CRIUCPQ, Quebec, Canada
1 shared publication- Clément Jambon-Barbara
Université Grenoble Alpes, INSERM U1300, HP2, and INSERM CIC1406, Grenoble, France (C.J.-B., C.K.).
1 shared publication
Latest Publications
- Open Access
- 17 February 2026
- Published by Wolters Kluwer Health in Circulation
- Vol. 153 (7) , 516-533
Breast Cancer Reveals Latent BMPR2 -Related Susceptibility to Pulmonary Hypertension
BACKGROUND: Pulmonary arterial hypertension (PAH) and breast cancer disproportionately affect women. BMPR2 (bone morphogenetic protein receptor type 2) mutations, the most common genetic cause of heritable PAH, also exert tumor-suppressive functions, but their role in linking these diseases remains unclear. METHODS: We combined bioinformatic, epidemiologic, and experimental approaches. Public cancer datasets were mined for BMPR2 alterations. In vivo, mammary tumor development and pulmonary hemodynamics were assessed in female Bmpr2 +/Δ71 rats with or without carcinogen (7,12-dimethylbenz[a]anthracene) exposure. Pulmonary arterial smooth muscle cells were exposed to tumor-conditioned media to test inflammatory proliferation. Finally, associations between breast cancer and PAH were examined in the French National Healthcare Database (9964 patients with PAH). RESULTS: BMPR2 expression was markedly reduced in human breast tumors, with recurrent somatic variants and deep deletions identified. Bmpr2 +/Δ71 rats exhibited spontaneous mammary tumors and, following 7,12-dimethylbenz[a]anthracene exposure, developed exacerbated pulmonary hypertension with increased vascular remodeling and inflammation. Tumor-bearing Bmpr2 +/Δ71 rats showed elevated lung IL-1β and NF-κB activation. In vitro, conditioned media from Bmpr2 +/Δ71 tumors induced proliferation of Bmpr2 +/Δ71 pulmonary arterial smooth muscle cells via IL-1β–dependent signaling, while neutralization of IL-1β attenuated this effect. Human pulmonary arterial smooth muscle cells carrying BMPR2 mutations similarly displayed heightened IL-1β–induced proliferation. Epidemiologically, breast cancer incidence was more than doubled in patients with PAH compared with the general population, and PAH incidence was increased nearly 9-fold among patients with breast cancer, indicating a bidirectional relationship. CONCLUSIONS: These findings identify a reciprocal association between breast cancer and PAH mediated by defective BMPR2 signaling and tumor-associated inflammation. Breast cancer may act as a “second hit,” unmasking BMPR2 -related susceptibility to PAH, underscoring BMPR2 as a shared molecular vulnerability with implications for surveillance of at-risk populations.
- 17 February 2026
- Published by Wolters Kluwer Health in Circulation
- Vol. 153 (7) , 516-533
Open AccessBreast Cancer Reveals Latent BMPR2 -Related Susceptibility to Pulmonary Hypertension
BACKGROUND: Pulmonary arterial hypertension (PAH) and breast cancer disproportionately affect women. BMPR2 (bone morphogenetic protein receptor type 2) mutations, the most common genetic cause of heritable PAH, also exert tumor-suppressive functions, but their role in linking these diseases remains unclear. METHODS: We combined bioinformatic, epidemiologic, and experimental approaches. Public cancer datasets were mined for BMPR2 alterations. In vivo, mammary tumor development and pulmonary hemodynamics were assessed in female Bmpr2 +/Δ71 rats with or without carcinogen (7,12-dimethylbenz[a]anthracene) exposure. Pulmonary arterial smooth muscle cells were exposed to tumor-conditioned media to test inflammatory proliferation. Finally, associations between breast cancer and PAH were examined in the French National Healthcare Database (9964 patients with PAH). RESULTS: BMPR2 expression was markedly reduced in human breast tumors, with recurrent somatic variants and deep deletions identified. Bmpr2 +/Δ71 rats exhibited spontaneous mammary tumors and, following 7,12-dimethylbenz[a]anthracene exposure, developed exacerbated pulmonary hypertension with increased vascular remodeling and inflammation. Tumor-bearing Bmpr2 +/Δ71 rats showed elevated lung IL-1β and NF-κB activation. In vitro, conditioned media from Bmpr2 +/Δ71 tumors induced proliferation of Bmpr2 +/Δ71 pulmonary arterial smooth muscle cells via IL-1β–dependent signaling, while neutralization of IL-1β attenuated this effect. Human pulmonary arterial smooth muscle cells carrying BMPR2 mutations similarly displayed heightened IL-1β–induced proliferation. Epidemiologically, breast cancer incidence was more than doubled in patients with PAH compared with the general population, and PAH incidence was increased nearly 9-fold among patients with breast cancer, indicating a bidirectional relationship. CONCLUSIONS: These findings identify a reciprocal association between breast cancer and PAH mediated by defective BMPR2 signaling and tumor-associated inflammation. Breast cancer may act as a “second hit,” unmasking BMPR2 -related susceptibility to PAH, underscoring BMPR2 as a shared molecular vulnerability with implications for surveillance of at-risk populations.
- 14 September 2024
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 64 (suppl 68) , PA1612
Narciclasine as a Novel Therapeutic Target for Pulmonary Arterial Hypertension: Addressing Glycosylation in Disease Pathophysiology.
Pulmonary arterial hypertension (PAH) is a life-threatening disease characterized by vasoconstriction and remodeling of pulmonary arteries, leading to increased pressure and right ventricle failure. This condition is associated with transcriptomic changes promoting metabolic disorders, inflammation, and a pro-survival phenotype in pulmonary artery smooth muscle cells (PASMCs). Transcriptomic analysis of PAH patient lung samples identified 4013 differentially expressed genes. Using pharmaco-transcriptomic databases, narciclasine emerged as a promising candidate. Hypothesizing narciclasine could counteract PAH, we administered it in a murine PAH model induced by monocrotaline. Results showed improvements in pulmonary hemodynamics, reduced right ventricular systolic pressure (RVSP), pulmonary artery acceleration time (PAAT), and total pulmonary resistance (TPR). Narciclasine treatment decreased inflammatory markers, PASMC proliferation, and vascular remodeling, promoting apoptosis. In vitro, narciclasine reduced PASMC proliferation and enhanced apoptosis, implicating glycosylation downregulation as its mechanism. This pathogenic factor in PAH was reversed by narciclasine, which also downregulated key glycosylation enzymes (both in vivo and in vitro), introducing a novel therapeutic pathway. Our study suggests that narciclasine may potentially improve PAH by targeting glycosylation. Utilizing a pharmaco-transcriptomic approach, our work indicates that narciclasine can enhance PAH outcomes both in vivo and in vitro.
- 14 September 2024
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 64 (suppl 68) , PA1612
Narciclasine as a Novel Therapeutic Target for Pulmonary Arterial Hypertension: Addressing Glycosylation in Disease Pathophysiology.
Pulmonary arterial hypertension (PAH) is a life-threatening disease characterized by vasoconstriction and remodeling of pulmonary arteries, leading to increased pressure and right ventricle failure. This condition is associated with transcriptomic changes promoting metabolic disorders, inflammation, and a pro-survival phenotype in pulmonary artery smooth muscle cells (PASMCs). Transcriptomic analysis of PAH patient lung samples identified 4013 differentially expressed genes. Using pharmaco-transcriptomic databases, narciclasine emerged as a promising candidate. Hypothesizing narciclasine could counteract PAH, we administered it in a murine PAH model induced by monocrotaline. Results showed improvements in pulmonary hemodynamics, reduced right ventricular systolic pressure (RVSP), pulmonary artery acceleration time (PAAT), and total pulmonary resistance (TPR). Narciclasine treatment decreased inflammatory markers, PASMC proliferation, and vascular remodeling, promoting apoptosis. In vitro, narciclasine reduced PASMC proliferation and enhanced apoptosis, implicating glycosylation downregulation as its mechanism. This pathogenic factor in PAH was reversed by narciclasine, which also downregulated key glycosylation enzymes (both in vivo and in vitro), introducing a novel therapeutic pathway. Our study suggests that narciclasine may potentially improve PAH by targeting glycosylation. Utilizing a pharmaco-transcriptomic approach, our work indicates that narciclasine can enhance PAH outcomes both in vivo and in vitro.